Back to Journals » The Application of Clinical Genetics » Volume 12

Update On The Clinical Perspectives And Care Of The Child With 47,XXY (Klinefelter Syndrome)

Authors Samango-Sprouse CA, Counts DR, Tran SL, Lasutschinkow PC, Porter GF, Gropman AL

Received 1 June 2019

Accepted for publication 20 September 2019

Published 23 October 2019 Volume 2019:12 Pages 191—202


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Martin H. Maurer

Carole A Samango-Sprouse,1–3 Debra R Counts,4 Selena L Tran,3 Patricia C Lasutschinkow,3 Grace F Porter,3 Andrea L Gropman5,6

1Department of Pediatrics, George Washington University, Washington, DC, USA; 2Department of Human and Molecular Genetics, Florida International University, Miami, FL, USA; 3The Focus Foundation, Davidsonville, MD, USA; 4Pediatric Endocrinology, Sinai Hospital, Baltimore, MD, USA; 5Department of Neurology, George Washington University, Washington, DC, USA; 6Division of Neurogenetics and Developmental Pediatrics, Children’s National Medical Center, Washington, DC, USA

Correspondence: Carole A Samango-Sprouse
The Focus Foundation, 820 W. Central Ave. #190, Davidsonville, MD 21035, USA
Tel +1 443-223-7323
Fax +1 855-550-8696

Abstract: 47,XXY (Klinefelter syndrome [KS]) is the most common sex chromosomal aneuploidy (1:660), yet, despite this, only 25% of the males are ever diagnosed. Males with 47,XXY present with characteristic symptoms throughout their lifetime with typical physical and neurodevelopmental manifestations focused in growth, cognitive development, endocrine function, and reproduction. Studies have demonstrated that optimal outcomes are dependent on early detection combined with consistent and targeted neurodevelopmental treatment throughout the lifespan. During infancy and into the preschool years, individuals with 47,XXY commonly face deficits in growth and development in the areas of early hormonal, motor, speech, and behavioral development. As they transition into school, the primary neurodevelopmental concerns include language difficulty, executive dysfunction, behavior, and learning and reading deficits. Adults with 47,XXY often present with taller than average height, low levels of fertility, azoospermia, and elevated gonadotropin levels. These presentations may persist from early childhood through adulthood but can be mitigated by appropriate interventions. Early neurodevelopmental and hormonal treatment has been shown to have a minimizing effect on the physical and neurodevelopmental manifestations in individuals with 47,XXY. With innovative and current research studies, the features common to the neurodevelopmental profile of 47,XXY have been further expanded and defined. Further research is necessary to elucidate and understand the relationship between the brain, behavior, and the phenotypic profile of 47,XXY.

Keywords: 47, XXY, Klinefelter syndrome, neurodevelopment, hormonal treatment

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]